Zoetis Inc. Files 8-K on Officer Changes and Compensation

Ticker: ZTS · Form: 8-K · Filed: 2025-10-28T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, compensation

Related Tickers: ZTS

TL;DR

Zoetis filed an 8-K detailing leadership changes and executive pay. Stay tuned for details.

AI Summary

Zoetis Inc. filed an 8-K on October 28, 2025, reporting events as of October 23, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This filing provides crucial updates on the company's leadership and executive compensation, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing standard board and officer changes, not indicating immediate financial distress or significant operational shifts.

Key Players & Entities

FAQ

What specific officer positions were affected by the changes reported in this 8-K?

The filing indicates "Departure of Directors or Certain Officers" and "Appointment of Certain Officers," but the specific positions are not detailed in the provided text.

Are there any details regarding new compensatory arrangements for officers mentioned in the filing?

The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specifics of these arrangements are not included in the provided text.

What is the primary reason for this 8-K filing?

The primary reasons are to report the departure/election/appointment of directors and officers, and to disclose compensatory arrangements, along with Regulation FD disclosures and financial statements/exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on October 23, 2025.

What is Zoetis Inc.'s principal executive office address?

Zoetis Inc.'s principal executive offices are located at 10 Sylvan Way, Parsippany, New Jersey 07054.

From the Filing

0001555280-25-000266.txt : 20251028 0001555280-25-000266.hdr.sgml : 20251028 20251028083344 ACCESSION NUMBER: 0001555280-25-000266 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251023 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251028 DATE AS OF CHANGE: 20251028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 251421622 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20251023.htm 8-K zts-20251023 0001555280 false 0001555280 2025-10-23 2025-10-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 23, 2025 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way Parsippany New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2025, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Stephanie Tilenius to the Board, effective as of December 1, 2025, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appoi

View on Read The Filing